ziconotide (Prialt)

amino acid sequence in first source; from venom of South Pacific sea cone snail, Conus magus; calcium channel blocker; administered by injection into Cerebrospinal Fluid; Prialt is synthetic form

Also Known As:

Prialt; SNX 111; CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2; SNX-111; leconotide; omega-conopeptide MVIIA; omega-conotoxin M VIIA; omega-conotoxin MVIIA; omega-conotoxin MVIIA, Conus magus

Networked: 227 relevant articles (49 outcomes, 46 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wallace, Mark S: 11 articles (09/2010 - 01/2004)
2.	Rauck, Richard L: 7 articles (11/2020 - 05/2006)
3.	Deer, Timothy R: 6 articles (01/2019 - 06/2009)
4.	Fisher, Robert: 6 articles (03/2009 - 01/2004)
5.	McDowell, Gladstone C: 5 articles (11/2020 - 07/2016)
6.	Webster, Lynn R: 5 articles (07/2015 - 05/2006)
7.	Swensen, Andrew M: 5 articles (12/2014 - 04/2008)
8.	Charapata, Steven G: 5 articles (02/2008 - 01/2004)
9.	Ellis, David: 5 articles (02/2008 - 06/2003)
10.	Dupoiron, Denis: 4 articles (10/2021 - 09/2012)

Related Diseases

1.	Pain (Aches) 11/01/2013 - "Across trials, ziconotide recipients had significantly greater reductions in pain intensity during ziconotide treatment than those receiving placebo (primary endpoint). " 07/01/2006 - "In double-blind, placebo-controlled studies, ziconotide significantly improved patient perception of pain from baseline to the end of the study periods, which ranged from 11 to 21 days. " 01/01/2006 - "In three pivotal, well designed trials of 5-6 or 21 days' duration, titrated ziconotide was significantly more effective than placebo in treating chronic malignant or nonmalignant pain as assessed by mean percentage improvements from baseline in Visual Analogue Scale Pain Intensity scores. " 03/01/2001 - "PAIN: In pivotal studies, ziconotide showed a significant reduction in pain compared to placebo. " 10/01/2006 - "Ziconotide was significantly more effective than placebo in the treatment of chronic malignant (p < 0.001) and non-malignant pain (p < 0.001). "
2.	Chronic Pain 05/01/2013 - "Ziconotide is a safe and effective strategy to treat chronic pain, although limitations remain, including a small therapeutic window. " 03/01/2012 - "Together, these in vitro data support the idea that a state-dependent, non-subtype-selective Ca(V)2 channel inhibitor can achieve an improved therapeutic window over the relatively state-independent Ca(V)2.2-selective inhibitor ziconotide in preclinical models of chronic pain." 03/01/2009 - "This open-label multicenter study evaluated the long-term safety and efficacy of intrathecal ziconotide and included 78 patients with chronic pain who had completed one of two previous ziconotide clinical trials. " 06/01/2009 - "Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain." 04/01/2008 - "An Open-Label, Multicenter Study of the Safety and Efficacy of Intrathecal Ziconotide for Severe Chronic Pain When Delivered via an External Pump."
3.	Neuralgia (Stump Neuralgia) 03/01/2022 - "Ziconotide is proposed to have efficacy for chronic neuropathic pain, with a favorable lack of tolerance and chemical dependency. " 09/01/2009 - "Additional studies are needed to establish the long-term efficacy and safety of ziconotide for neuropathic pain." 09/01/2009 - "Evidence from DBPC trials, open-label studies, case series, and case studies suggests that ziconotide, as either monotherapy or in combination with other IT drugs, is a potential therapeutic option for patients with refractory neuropathic pain. " 09/01/2009 - "In the preclinical studies, ziconotide demonstrated antiallodynic effects on neuropathic pain. " 10/01/2019 - "Recently ziconotide has been approved for use both neuropathic and non-neuropathic pain. "
4.	Intractable Pain 12/15/2014 - "There is also human validation data from ziconotide, the CaV2.2-selective peptidyl inhibitor used clinically to treat refractory pain. " 07/01/2009 - "Although ziconotide is approved by the US Food and Drug Administration for monotherapy, it is sometimes used in combination with other intrathecal drugs for the management of intractable pain conditions in clinical practice. " 06/01/2006 - "Ziconotide: a new option for refractory pain." 09/01/2005 - "Ziconotide may represent another option for patients with refractory pain." 07/01/2004 - "Until a new approach with a better effectiveness/adverse effects profile than ziconotide for refractory pain emerges, further optimisation of ziconotide for use in the treatment of refractory pain should be undertaken."
5.	Cancer Pain 12/01/2016 - "Ziconotide has also shown efficacy for reduction of cancer-related pain; however, proper dosing and titration must be used to prevent adverse events. " 08/01/2023 - "Ziconotide for the Management of Cancer Pain: A Budget Impact Analysis." 01/01/2020 - "How has ziconotide impacted non-cancer pain management?" 01/01/2018 - "If ITA is deemed necessary, ziconotide is a rational alternative, at least in chronic (neuropathic) non-cancer pain. " 10/01/2016 - "Intrathecal ziconotide, indicated as a first-line drug in non-cancer pain, could be proposed in such cases. "

Related Drugs and Biologics

1.	Analgesics (Analgesic Drugs)
2.	Opioid Analgesics (Opioids)
3.	Morphine (MS Contin)
4.	Calcium Channel Blockers (Blockers, Calcium Channel)
5.	N-Type Calcium Channels (N-Type Calcium Channel)
6.	Calcium Channels (Calcium Channel)
7.	Conotoxins (Conotoxin)
8.	Baclofen
9.	Peptides (Polypeptides)
10.	Non-Narcotic Analgesics (Analgesics, Non Narcotic)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Ligation
4.	Drug Therapy (Chemotherapy)
5.	Catheters